CYTH Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 bal. 2024 @ 23:00):

Stats
Šios dienos apimtis	28 089.00
Vidutinė apimtis	100 379
Rinkos kapitalizacija	36.18M
EPS	$0 ( 2024-03-18 )
Kita pelno data	( $0 ) 2024-05-13
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.020
ATR14	$0.0120 (0.95%)

Insider Trading

Date	Person	Action	Amount	type
2024-02-13	Sieger Markus	Buy	14 004	Common Stock
2024-02-13	Ostronic Francis Patrick	Buy	8 703	Common Stock
2024-02-13	Toig Randall M.	Buy	7 516	Common Stock
2024-02-13	Strattan Ce Rick	Buy	6 963	Common Stock
2024-02-13	Wong Vivien	Buy	6 330	Common Stock

INSIDER POWER
50.71
Last 99 transactions
Buy: 16 269 213 \| Sell: 5 479 045

Cyclo Therapeutics, Inc. Koreliacija

10 Labiausiai teigiamai susiję koreliacijos
STRO	0.944
ASPU	0.94
LSXMK	0.922
LSXMA	0.922
PRTG	0.917
NAKD	0.917
BOCH	0.915
SIRI	0.911
ACRX	0.91
BFRI	0.91

10 Labiausiai neigiamai susiję koreliacijos
PAE	-0.928
RMRM	-0.927
APOP	-0.916
PESI	-0.907
EBSB	-0.905
INTA	-0.905
LMNR	-0.905
NCAC	-0.903
NVDA	-0.903
FTNT	-0.902

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Cyclo Therapeutics, Inc. Finansinės ataskaitos

Annual	2023
Pajamos:	$1.08M
Bruto pelnas:	$-2.41M (-223.91 %)
EPS:	$-1.230

FY	2023
Pajamos:	$1.08M
Bruto pelnas:	$-2.41M (-223.91 %)
EPS:	$-1.230

FY	2022
Pajamos:	$1.38M
Bruto pelnas:	$1.24M (89.90 %)
EPS:	$-1.810

FY	2021
Pajamos:	$1.59M
Bruto pelnas:	$1.43M (90.16 %)
EPS:	$-2.24

Financial Reports:

No articles found.

Cyclo Therapeutics, Inc.

Cyclo Therapeutics, Inc., a clinical stage biotechnology company, develops cyclodextrin-based products for the treatment of various diseases. Its lead drug candidate is Trappsol Cyclo, an orphan drug, which is Phase III clinical trials for the treatment of Niemann-Pick Type C disease. The company also develops Trappsol Cyclo for the treatment of Alzheimer's disease. In addition, it sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs. The company was formerly known as CTD Holdings, Inc. and changed its name to Cyclo Therapeutics, Inc. in September 2019. Cyclo Therapeutics, Inc. was incorporated in 1990 and is based in Gainesville, Florida.